KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

AbCellera Biologics (ABCL) Depreciation & Amortization (IS) (2020 - 2023)

Historic Depreciation & Amortization (IS) for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to $7.5 million.

  • AbCellera Biologics' Depreciation & Amortization (IS) fell 4546.24% to $7.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $24.4 million, marking a year-over-year decrease of 1238.69%. This contributed to the annual value of $90.8 million for FY2024, which is 27241.24% up from last year.
  • Latest data reveals that AbCellera Biologics reported Depreciation & Amortization (IS) of $7.5 million as of Q4 2023, which was down 4546.24% from $5.7 million recorded in Q3 2023.
  • In the past 5 years, AbCellera Biologics' Depreciation & Amortization (IS) ranged from a high of $13.8 million in Q4 2022 and a low of $41000.0 during Q3 2020
  • For the 4-year period, AbCellera Biologics' Depreciation & Amortization (IS) averaged around $4.5 million, with its median value being $4.0 million (2021).
  • As far as peak fluctuations go, AbCellera Biologics' Depreciation & Amortization (IS) skyrocketed by 884146.34% in 2021, and later tumbled by 4546.24% in 2023.
  • Over the past 4 years, AbCellera Biologics' Depreciation & Amortization (IS) (Quarter) stood at $3.3 million in 2020, then grew by 18.93% to $4.0 million in 2021, then soared by 249.12% to $13.8 million in 2022, then plummeted by 45.46% to $7.5 million in 2023.
  • Its Depreciation & Amortization (IS) was $7.5 million in Q4 2023, compared to $5.7 million in Q3 2023 and $5.6 million in Q2 2023.